Trials / Completed
CompletedNCT03971279
Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis
Long Term Efficacy of Dexamethasone Intravitreal Implant (Ozurdex®) in Treatment of Recurrent VKH Uveitis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 16 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.
Detailed description
Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done. Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone Ophthalmic implant | intravitreal injection of ozurdex implant |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2019-11-22
- Completion
- 2019-11-22
- First posted
- 2019-06-03
- Last updated
- 2019-11-26
Locations
1 site across 1 country: United Arab Emirates
Source: ClinicalTrials.gov record NCT03971279. Inclusion in this directory is not an endorsement.